Sort   by:  
 Page size 
ProteomicsThe secretome features associated with the development of re-sistance to vemurafenib in BRAFV600E mutated colon cancer cells
Patients with metastatic colorectal cancer (mCRC) carrying BRAFV600E mutation have worse response to chemotherapy and poor prognosis. The aim of this study was to conduct for the first time comparative proteomics profiling of the secretome from vemurafenib-sensitive vs. resistant colon cancer cells ...
ORGANISM(S): Homo sapiens (Human) 
2023-04-29 | PXD039766 | Pride
Brafv600e Braf inhibition Hspa5/ grp78 Colon cancer Rpa1 Er stress Vemurafenib Secretome Chemoresistance Dna replication Lc-ms/ms 
ProteomicsEzrin inhibition overcomes acquired resistance to vemurafenib in BRAFV600E-mutated colon cancer and melanoma cells in vitro
In spite of the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facili...
ORGANISM(S): Homo sapiens (Human) 
2023-08-29 | PXD042499 | Pride
Ezrin Brafv600e Actin cytoskeleton Nsc305787 Colon cancer Ezrin inhibitor Melanoma Braf inhibitor Vemurafenib 
Sort   by:  
 Page size